The Harefield Acute Myocardial Infarction Cohort

STATUS

Recruiting
End date

Dec 31, 2035
participants needed

2000
sponsor

Royal Brompton & Harefield NHS Foundation Trust

Send

Updated on 19 February 2024

See if I qualify

heart disease

cardiomyopathy

angiography

myocardial infarction

infarct

acute coronary syndrome

percutaneous coronary intervention

unstable angina

angina pectoris

Summary

Show definitions

In this project the investigator's plan to collect blood during a patient's routine angiogram procedure which they will have due to having suffered a heart attack. Data from the patients' routine procedures for this condition, including but not exclusively, ECG, Echocardiogram, MRI scans, will be collected. The aim of the research project is to analyse the blood samples and identify novel biomarkers and clinical parameters associated with acute coronary syndromes. The investigator's will particularly focus on markers of inflammation and micro-organism activity. The investigator's hope that this will help to gain more knowledge about what causes heart disease and how various conditions can be treated more efficiently. The investigator's will follow-up and collect further research data via a questionnaire at the routine 6 weeks and 6 months follow-up appointment after the angiogram procedure. Participants will also be telephoned at one-year post procedure, to update any events and medication status and data will thereafter be collected form data held by the hospital without having to contact the participant. Remaining blood samples will be stored securely for further analysis into blood and other markers.

Description

Acute coronary syndromes (ACS), i.e. patients presenting with ST-segment elevation myocardial infarction (STEMI), non ST-segment elevation myocardial infarction (non-STEMI) or unstable angina, are still a major cause of morbidity and mortality in the United Kingdom and beyond. In spite of the enormous progress made in the last decades, the in hospital mortality has plateaued recently, and the event rate after the infarction is still high with one in 8 patients having a second event (i.e. death, myocardial infarction, heart failure, revascularization among others) within a year of follow-up.

After the acute event, risk stratification is important and will be come even more sophisticated than it currently is with the advent of anatomic risk scores (SYNTAX II Score), novel biomarkers and novel drugs allowing for more precise characterization of the patients individual risk and more tailored secondary prevention strategies (Precision Medicine).

Indeed, particularly the upcoming treatment strategies with bio-logicals (i.e. monoclonal antibodies, e.g. against PCSK9) and genetic tools (i.e. RNA interference, antisense technology) will require precise risk assessment for cost-effective use of these promising new tools.

It is anticipated that this study will help the investigator's to describe the heart attack population in a robust manner with a wealth of clinical data as well as blood samples for bio-markers.

Details

Condition	Acute Coronary Syndrome, Ischemic Heart Disease
Age	100years or below
Treatment	60mls of blood donated for research analysis
Clinical Study Identifier	NCT04218344
Sponsor	Royal Brompton & Harefield NHS Foundation Trust
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	All patients presenting to Harefield Hospital through the Primary Percutaneous
	Coronary Intervention programme, with ST-segment elevation myocardial
	infarction, non ST-segment elevation myocardial infarction, unstable angina
	Tako Tsubo syndrome, spontaneous coronary artery dissection and acute
	myocarditis, with the intention to assess with coronary angiography
Exclusion Criteria
	Patients will be able to self-exclude if they do not provide full informed consent
	Every effort will be made to obtain informed consent from all patients
	Patients who do not survive the hospital episode will undergo a Professional or Personal Consultee process of assumed consent

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

heart disease

cardiomyopathy

angiography

myocardial infarction

infarct

acute coronary syndrome

percutaneous coronary intervention

unstable angina

angina pectoris

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

The Harefield Acute Myocardial Infarction Cohort